For Mental Health Awareness Month, David J. Hellerstein, MD, discusses psychedelic drugs as they pertain to treating mental health disorders.
“In recent years, we now have an incredible new development: the renewed interest in psychedelic drugs, whether classic psychedelics like psilocybins and empathogens like MDMA, or dissociative psychedelics like ketamine,” Hellerstein, a professor of clinical psychiatry at Columbia University Medical Center, told Healio.
Hellerstein is also director of the Depression Evaluation Service in Columbia University department of psychiatry and a